SML1611

Lafutidine

≥98% (HPLC)

• Sinónimos: (Z)-2-((Furan-2-ylmethyl)sulfinyl)-N-(4-((3-(piperidin-1-ylmethyl)pyridin-2-yl)oxy)but-2-en-1-yl)acetamide, 2-[(2-Furanylmethyl)sulfinyl]-N-[(2Z)-4-[[4-(1-piperidinylmethyl)-2-pyridinyl]oxy]-2-buten-1-yl]-acetamide
• Fórmula empírica (notación de Hill): C₂₂H₂₉N₃O₄S
• Número de CAS: 118288-08-7
• Peso molecular: 431.55
• MDL number: MFCD00867520
• UNSPSC Code: 12352200
• PubChem Substance ID: 329825497
• NACRES: NA.77

Propiedades

• Quality Level: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 20 mg/mL, clear
• storage temp.: −20°C
• SMILES string: O=C(CS(CC1=CC=CO1)=O)NC/C=C\COC2=NC=CC(CN3CCCCC3)=C2
• InChI: 1S/C22H29N3O4S/c26-21(18-30(27)17-20-7-6-14-28-20)23-9-2-5-13-29-22-15-19(8-10-24-22)16-25-11-3-1-4-12-25/h2,5-8,10,14-15H,1,3-4,9,11-13,16-18H2,(H,23,26)/b5-2-
• InChI key: KMZQAVXSMUKBPD-DJWKRKHSSA-N

Descripción

Biochem/physiol Actions

Lafutidine is a second generation H2 histamine receptor antagonist. Lafutidine has been used clinically to treat ulcers and gastro-esophageal reflux disease (GERD). Lafutidine has also been investigated as a treatment against peripheral neuropathy and for its protective stomach effects during cancer chemotherapies and long term ibuprofen use.

Información de seguridad

• pictograms: GHS07
• signalword: Warning
• hcodes: H302
• pcodes: P264 - P270 - P301 + P312 - P501
• Hazard Classifications: Acute Tox. 4 Oral
• Storage Class: 11 - Combustible Solids
• wgk_germany: WGK 1
• flash_point_f: Not applicable
• flash_point_c: Not applicable